June 30, 2023 11:21 AM EDT

Genfit, Ipsen tout pivotal trial readout for rare liver disease, head toward FDA and EMA submissions

Lei Lei Wu

News Reporter

Genfit and Ipsen announced Friday morning that their experimental treatment elafibranor helped patients with primary biliary cholangitis, a rare liver disease, see a decrease in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Genfit, Ipsen tout pivotal trial readout for rare liver disease, head toward FDA and EMA submissions

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

FTC to sue major PBMs over insulin rebates, claiming they inflated patient cost

Biotech VC firm outlines plans for $100M fund

Novo says its CB1 drug helped shed weight, but efficacy and safety questions remain

Why did Eli Lilly ask a patient on a compounded GLP-1 drug for their medical information?

FDA OKs the first-ever self-administered vaccine, for flu

Breaking down silos with a new quantitative approach to drug development

Gen­fit, Ipsen tout piv­otal tri­al read­out for rare liv­er dis­ease, head to­ward FDA and EMA sub­mis­sions

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Genfit, Ipsen tout pivotal trial readout for rare liver disease, head toward FDA and EMA submissions